ArticleInternal medicine (Tokyo, Japan)2025

Alternating Administration of Osimertinib for Leptomeningitis and Docetaxel Plus Ramucirumab for Lung Adenocarcinoma Resistant to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Haruka Tomizawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.